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Abstract
This review summarises theoretical studies attempting to assess the population impact of
antiretroviral therapy (ART) use on mortality and HIV incidence. We describe the key parameters
that determine the impact of therapy, and argue that mathematical models of disease transmission
are the natural framework within which to explore the interaction between antiviral use and the
dynamics of an HIV epidemic. Our review focuses on the potential effects of ART in resource-poor
settings. We discuss choice of model type and structure, the potential for risk behaviour change
following widespread introduction of ART, the importance of the stage of HIV infection at which
treatment is initiated, and the potential for spread of drug resistance. These issues are illustrated
with results from models of HIV transmission. We demonstrate that HIV transmission models
predicting the impact of ART use should incorporate a realistic progression through stages of HIV
infection in order to capture the effect of the timing of treatment initiation on disease spread. The
realism of existing models falls short of properly reproducing patterns of diagnosis timing,
incorporating heterogeneity in sexual behaviour, and describing the evolution and transmission of
drug resistance. The uncertainty surrounding certain effects of ART, such as changes in sexual
behaviour and transmission of ART-resistant HIV strains, demands exploration of best and worst
case scenarios in modelling, but this must be complemented by surveillance and behavioural surveys
to quantify such effects in settings where ART is implemented.
Introduction
The epidemiological impact of widescale use of (highly
active) antiretroviral therapy (HAART, or ART) among
HIV patients in industrialised countries has been explored
by a number of mathematical modelling studies [1-5].
The consequences of ART use are far from intuitive. Suc-
cessful ART decreases plasma [6] and seminal viral load
[7,8] and so is thought to reduce HIV infectiousness.
However, its main function is to increase the life expect-
ancy of infected individuals [9,10], and over time this
causes the pool of potential transmitters of infection to
grow. These two factors – decreased infectivity but
increased duration of infectiousness – have opposing
effects on transmission. In addition, increases in risk
behaviour could result from increased optimism about
HIV prognosis due to the availability of ART. This is an
area of uncertainty, with contradictory evidence [11-15].
Mathematical models can be used to address questions
regarding the potential impact and effectiveness of various
strategies. In terms of ART use, they can be used to
investigate:
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1) optimising the efficient use of ART;
2) the epidemiological consequences of ART and interac-
tion with behavioural changes/interventions;
3) the likely course of drug resistance evolution
a. Within the individual;
b. Between individuals;
4) achievable levels of coverage and effectiveness;
5) the effective and efficient use of second line treatments;
and
6) demographic/health care impact.
This review will briefly describe a range of models investi-
gating the impact of ART use in various settings and eval-
uate the utility of these dynamic models.
The range of ART models
Mathematical models examining the epidemiological
impact of ART broadly fall into two categories; those
incorporating HIV transmission dynamics, where inci-
dence of new infections is dependent on HIV prevalence
[1,2,4,5], and simpler linear models [16-18]. A summary
of ART models is provided in Table 1. Aalen et al [17] con-
structed a model describing men who have sex with men
(MSM) in England and Wales and the use of ART. This
Markov multi-stage model represented stages of HIV
infection based on CD4 count. The authors considered a
variety of treatment scenarios, and incorporated asympto-
matic and symptomatic individuals and the concept of eli-
gibility for treatment, making the simulation of treatment
uptake and its impact more realistic than previous work.
Wood et al [16] constructed a health economic model to
predict the future impact of low-level ART use in South
Africa from 2000 to 2005. The authors modelled total
drug cost, cost per life year gained and the proportion of
per person healthcare expenditure required to finance
ART in each scenario. The study involved a cost effective-
ness analysis comparing the epidemiological impact of
ART with other interventions such as prevention of
mother-to-child transmission (PMTCT). Freedberg et al
[18] also used stages of disease determined by CD4 count
and predicted the incremental cost per quality-adjusted
year of life gained by ART in the US. Wilson and Blower
[19] used a spatial mathematical model to explore ART
allocation strategies among health care facilities in the
province of KwaZulu-Natal, South Africa, with an empha-
sis on maximising equity in access to treatment.
In an investigation into the impact of an expanded
response (incorporating prevention interventions and
care and support activities) on the HIV/AIDS pandemic,
Stover et al 2002 did not include the effect of ART because,
"there is little empirical data available on the magnitude
of the preventive effect of treatment (reduced viral load
and hence infectiousness) and care" [20]. However in a
later publication, the authors investigated the effects of
combining treatment with effective prevention efforts,
using the same model (the Goals model [21]), calibrated
to sub-Saharan Africa [22]. The Goals model is a Microsoft
Excel™ spreadsheet model using linear equations,
designed to improve resource allocation for national HIV/
AIDS programmes. It feeds into the dynamic epidemic
projection package (EPP) and Spectrum, used by the
UNAIDS/WHO to produce national HIV/AIDS estimates
[23,24], to predict the impact of an intervention. The
authors concluded that a prevention-centred strategy pro-
vides greater reductions in incidence, but more modest
mortality benefits, than treatment-centred scenarios. A
combined approach would yield further benefits, but
focusing on treatment at the expense of prevention could
diminish this effect.
Auvert et al 2004 used a linear model to estimate the pro-
portion of the South African population requiring ART
under the then current WHO guidelines (treating all indi-
viduals with a CD4 cell count less than 200 cells/mm3
[25]) and to predict the impact of ART on the short term
spread of HIV in this setting [26].
Such linear models have generally been used to inform
policy makers on issues such as resource allocation, and
typically involve only short-term predictions of the effect
of ART for health care providers, as estimated by cost-
effectiveness analysis [16,18]. The models are relatively
straightforward in that they look at the health states of
individuals, associated treatments and events that individ-
uals experience, but fail to take account of the non-linear
feedback process underlying infectious disease epidemics.
Linear models are limited by the accuracy of estimates of
HIV incidence used to parameterise the models, which is
all the more important because their predictions and con-
clusions are usually more quantitative in nature than
those provided by dynamic models, which have tended to
be used to give more qualitative insight. Models incorpo-
rating HIV transmission dynamics typically investigate the
impact of ART over a longer time frame and are used to
address more general questions surrounding ART use,
such as whether the benefits of ART provision outweigh
the problems and risks, and which approaches to ART
provision are most effective. Both types of model are
required, to inform policy makers in resource-poor set-
tings about the costs of ART provision in the short term
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Table 1: Summary of existing ART models, by date of publication.
Study Model structure Setting Assumptions Key outcomes (pertaining to ART) 
and comments
Zaric et al 1998 [74] Dynamic, difference 
equations
MSM and IDU, US cities/
regions
Infection stratified into HIV and AIDS 
stages. Allows acquired and transmitted 
drug resistance. Rate of resistance 
evolution: 95% per year for non-adherents, 
5% per year for adherents. Increased life 
expectancy due to ART: 1.5-fold for 
adherents, 1.2-fold for non-adherents, 1.2-
fold for adherents infected with drug 
resistant HIV.
The most important factor affecting 
emergence of drug resistance is adherence 
to ART.
Aalen et al 1999 [17] Linear MSM, England and Wales, 
1990s
Markov multi stage model (stage based on 
CD4 count). Explicit diagnosis and 
treatment. Estimated HIV incidence in the 
MSM population, which was fixed at 1200 
cases/year for all but one scenario, where 
incidence was halved from 1995 onwards.
Decrease in AIDS incidence due to ART. 
Number receiving treatment will increase 
50–100% by 2001 compared to pre-1996.
Wood et al 2000 [75] Linear model IDU, Vancouver, Canada 
1999–2006
Treatment uptake: 80% (scenario 1), 20% 
(scenario 2). Median increase in life 
expectancy due to ART: 7 years. No drug 
resistance or stratification by infection 
stage or sexual activity class. Prevalence 
estimates used in DemProj, part of the 
Spectrum suite of models (information at 
http://www.futuresgroup.com/software/
Goals/goals.pdf) (3 scenarios: prevalence 
reduced from 7% in 1999 to 5% in 2006, 
prevalence remains at 7%, prevalence 
increases to 9% in 2006.
Calculated life expectancy and AIDS deaths 
1999–2006 for each scenario. Concluded 
that low level ART use is not sufficient to 
increase life expectancy in this population 
and called for expansion in ART coverage.
Wood et al 2000 [16] Linear health economic 
model (based on previous 
model [75])
South Africa 2000–2005 Median increase in life expectancy due to 
ART: 6 years (range: 5–7). Treatment 
uptake: 25% of infected adults. Spectrum 
AIDS Impact model was used to adjust the 
population projections for current and 
projected HIV-associated mortality.
Providing ART for 25% of the infected 
population could prevent a 3.1 year decline 
in life expectancy and more than 430,000 
incident cases, but with disproportionate 
expenditure ($19 billion at 2000 prices) 
compared to preventing mother-to-child 
transmission.
Blower et al 2000 [5] Dynamic, deterministic MSM, San Francisco, US, up 
to 2010
Changes in sexual behaviour: no change to 
doubling of risk. Treatment coverage rates: 
50–90% uptake per year. ART reduces 
infectivity 2- to 100-fold. Acquired drug 
resistance: 10–60% per year (infections can 
revert back to ART-sensitive). Resistance 
is transmitted, but is less fit than wild type. 
No stratification by stage of infection or 
sexual activity class. Increased life 
expectancy due to ART: 1.5- to 3.0-fold.
Increasing ART usage would decrease the 
death rate and substantially reduce HIV 
incidence (wide range of results due to 
uncertainty in parameter estimations).
Blower et al 2001 [63] Dynamic, deterministic 
(used previous model [5])
MSM, San Francisco, US, 
1996–2005
Treatment uptake and drug resistance 
evolution rates as for [5]. No change in 
risk behaviour. Assumed no resistant 
strains could arise that were as 
transmissible as wild type. Transmissibility 
range: 1–90% as fit as wild type. Implicitly 
allows superinfection with wild type virus 
of subjects with primary resistance.
Prevalence of ART resistance is already 
high in San Francisco and will continue to 
increase substantially through 2005. 
Transmitted drug resistance will remain 
low, only increasing gradually, with a 
doubling time of around 4 years and a 
predicted median 15.6% (range 0.05–
73.21%) new infections resistant to ARVs 
by 2005.
Freedberg et al 2001 [18] Linear health economic 
model
US Monte Carlo simulation of a hypothetical 
cohort of infected patients. Disease 
progression predicted by CD4 count (6 
categories) and viral load (5 categories). 
Detailed description and associated costs 
of HIV-related morbidity, opportunistic 
infections and death. Virologic failure 
represented as 0.5 log increase in viral load 
for 2 consecutive months. Increased life 
expectancy due to ART: 2 years.
The cost-effectiveness ratio for ART was 
$13,000–$23,000 per quality-adjusted life 
year gained. Initial CD4 count and drug 
costs were the most important 
determinants of costs, clinical benefits, and 
cost effectiveness.
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Tchetgen et al 2001 [76] Dynamic, deterministic MSM (assumes same 
population as Blower et al 
[5])
No stratification by sexual activity or stage 
of infection (model is for all stages except 
AIDS; progression to AIDS exits an 
individual from the model population). 
Models diagnosis separately from 
treatment initiation. No sexual behaviour 
change due to ART. Drug resistance 
emerges at 1.2–13.5% per year for 
adherent patients and 67.3–85.9% per year 
for non-adherent patients. Resistant strains 
are half as transmissible as wild type. 
Untreated resistant infections may revert 
to wild type infections (10% per year). 60% 
of treated patients adhere. Increased life 
expectancy due to ART: approximately 3-
fold. ART reduces infectivity by 74%. 
Withdrawal rates also vary by adherence.
Although screening for adherence is likely 
to reduce levels of drug resistance 
compared to treating all patients, HIV and 
AIDS incidence rates are likely to increase 
unless screening accuracy is extremely 
high.
Dangerfield et al 2001 [77] Dynamic, deterministic MSM, UK 1981–1998 Five stages of infection with varying 
infectivity broadly corresponding to 
primary infection, incubation, pre-AIDS 
and early and late AIDS. Three levels of 
sexual activity with proportionate mixing. 
No drug resistance. Proportion initiating 
ART at each stage (models 1,2 and 3 
respectively): incubation = 0%, 0%, 60%; 
preAIDS = 0%, 10%, 25%; early stage AIDS 
= 0%, 10%, 35%. No uptake for late stage 
AIDS, which is defined as the final few 
months of care – authors assume patients 
only reach this stage as a result of 
treatment failure. Infectivity decreases to a 
constant level for all those treated, which 
is 35–40-fold less than for pre-AIDS.
Three models were designed, differing by 
prognosis of patients experiencing 
treatment failure for models 1 and 2. 
Model 3 stratifies life expectancy on ART 
by stage of infection at which treatment is 
initiated.
Law et al 2001 [4] Dynamic, deterministic MSM, Australia 1996 Population-level changes in sexual 
behaviour: no change to doubling of risk. 
Decrease in infectivity due to ART: 10-fold 
(range: 100-fold to none). Proportion of 
individuals diagnosed and treated increases 
with progression of disease, as determined 
by CD4 count. HIV diagnosis modelled 
separately to ART initiation, median 2-fold 
decrease in risk behaviour upon diagnosis 
(range: 25–75% reduction). No 
stratification by sexual activity group. No 
incorporation of drug resistance. Stratified 
by stage of infection in terms of CD4 count 
(>500 cells/ml, 200–500, <200, AIDS). 
Proportion treated by disease stage: >500 
= 35%, 200–500 = 52%, <200 = 72%, AIDS 
= 90%.
Changes in risk behaviour were linearly 
associated with increases in incidence, 
while decreases in infectivity were non-
linearly associated with decreases in 
incidence. Decreases in infectivity of 2-, 5- 
and 10-fold would be counterbalanced (in 
terms of incidence) by increases in risk 
behaviour of 40, 60 and 70%, respectively.
Velasco-Hernandez et al 
2002 [1]
Dynamic, deterministic 
(used previous model [5])
MSM, San Francisco, US, Previous model [5] is used to derive an 
analytical expression for R0. Used 
assumptions as for the previous model. 
Changes in risk behaviour: 50% reduction 
to 100% increase (whole population). 
Relative fitness of resistant strains: 1% to 
"approximately as transmissible".
Median R0 = 0.90 if risky sex decreased, 1.0 
if risky sex remained stable, and 1.16 if 
risky sex increased. R0 decreased as ART 
coverage increased. The probability of 
epidemic eradication is high (p = 0.85) if 
risky sex decreases (median 25% 
reduction), moderate (p = 0.5) if it remains 
stable, and low (p = 0.13) if it increases 
(median 50% increase). Concluded that 
ART can function as an effective HIV 
prevention tool, even with high levels of 
drug resistance and risky sex, and could 
eradicate a high prevalence (30%) HIV 
epidemic.
Law et al 2002 [78] Dynamic, deterministic 
(extension of previous 
model [4])
MSM, Australia 1996 Incorporation of other sexually 
transmitted infections (STI), but not 
dynamically-assumed 100% increase in 
prevalence of STI among all MSM 
regardless of HIV status, due to increased 
risk behaviour as a result of ART 
introduction. STI infection increased HIV 
infectivity 3.5-fold (range: 2–5-fold).
Decreases in infectivity of 2-, 5- and 10-
fold would be counterbalanced (in terms of 
incidence) by increases in risk behaviour of 
30, 50 and 65%, respectively i.e. even more 
modest increases than in previous 
publication [4]. Even small increases in STI 
as a result of increased risk behaviour 
could have an important multiplicative 
effect increasing HIV incidence.
Table 1: Summary of existing ART models, by date of publication. (Continued)
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Johnson & Dorrington 
2002 [79]
ASSA2000 Interventions 
Model (dynamic, 
deterministic spreadsheet 
model)
South Africa Stages of infection: stages I to IV of the 
WHO clinical staging system, with decline 
in sexual activity at advanced stages. 
Includes voluntary counselling and testing 
(VCT) with a corresponding (though 
transient) decrease in risk behaviour for 
both infected and uninfected individuals. 
Reduction in viral load due to ART: 1.76 
log10. Reduction in infectivity: 67% per log 
reduction in viral load. 4 sexual activity 
classes. Only AIDS patients qualify for 
treatment. Model assumes a phased roll-
out achieving 90% coverage by 2006. First 
6 months of ART: death rate = 8.2%, 
discontinuation rate = 9.1%. Thereafter: 
death rate = 5.8%/year, discontinuation 
rate = 5.8%. Resistance not explicitly 
modelled.
ART provision is highly effective at 
preventing new infections, through 
reduced infectivity and assumed impact of 
VCT, and the high coverage level. ART plus 
VCT reduces incidence of AIDS, but 
because of increasing numbers starting 
treatment, the overall number of AIDS 
cases increases to a peak in 2015. 
Approximately one million deaths would 
be averted between 2001 and 2015 if ART 
is added to a set of AIDS prevention 
initiatives.
Nagelkerke et al 2002 [80] Dynamic, deterministic Botswana and India Stratified by gender and 2 sexual activity 
groups (higher group represents CSWs 
and their clients). No changes in sexual 
behaviour due to ART, but "effective 
counselling" of those on ART could 
decrease infectivity of those developing 
drug resistance by 50%. ART reduces 
infectivity to zero. Rate of acquired 
resistance: 25% per year (range: 5–25%). 
Transmitted resistance possible (resistant 
strains appear to be as transmissible as 
wild type). Rate of treatment uptake: all 
those infected are recruited at rate 50% 
per year. No stratification by stage of 
infection.
Compared impacts of an ART programmes 
to other HIV interventions. Concluded 
that after transient success, ART would be 
ineffective within 30 years due to 
widespread drug resistance. Assumes high 
treatment uptake rates and pessimistic 
assumptions regarding transmission of drug 
resistant strains.
Gray et al 2003 [2] Dynamic, stochastic Rakai, Uganda, 2000–2020 Assumes ART reduces HIV log viral load 
by 27.0–42.5%, representing decreases in 
log viral load from 5.32 to 3.06 log10 
copies/ml [49], and 5.23 to 3.82 log10 
copies/ml [48]. These generate an average 
decrease in infectivity of 95.7% (0.0023 to 
0.0001 per coital act) and 43.5% (0.0023 to 
0.0013) respectively. Sexual activity 
decreases with increasing viral load. 
Behavioural disinhibition: increased risk by 
50–100% (among those on ART only). 
Treatment uptake: scenario 1: all with viral 
load >55,000 copies/ml; scenario 2: all 
subjects, irrespective of viral load (20% of 
infected persons in Rakai had viral loads 
>55,000 copies/ml [81]). Range of 
treatment coverage: 0–100%.
Concluded that ART alone cannot control 
mature HIV epidemics such as that in 
Rakai. Behavioural disinhibition would 
counter decreases in HIV infectivity due to 
ART.
Xiridou et al 2003 [82] Dynamic, deterministic Young MSM, Amsterdam, 
The Netherlands
Steady and casual partnerships. Stages of 
infection: primary, incubation, AIDS. Sexual 
activity assumed to cease after 
development of AIDS. 42% subjects in 
incubation stage are diagnosed. Diagnosis 
during incubation results in a 25% (0–50%) 
reduction in risky behaviour. ART reduces 
infectivity by 74.5%. Increased life 
expectancy (before development of AIDS) 
due to ART: 9.5 years.
A 75–99% reduction in infectivity due to 
ART will be counterbalanced by increases 
of 50% (range: 30–80%) in risky behaviour 
with steady partners, but not by increases 
of up to 100% with casual partners. 
Increasing HIV testing from 42% to 80% 
and ART coverage from 70% to 85%, 
would mean even a 100% increase in risk 
taking with steady partners would not 
outweigh the effect of ART on HIV 
incidence.
Xiridou et al 2004 [3] Dynamic, deterministic 
(extension of previous 
model [82])
Young MSM, Amsterdam, 
The Netherlands
Extension of original model [3] to allow for 
initiation of ART during primary infection. 
Proportion of men diagnosed during 
incubation and successfully treated: 60–
80%. Proportion initiating ART during 
primary infection: 1–10%. ART reduces 
infectivity during incubation by 50–99%. 
Population-level increase in risk behaviour 
for both steady and casual partnerships: 0–
100%. Mean incubation time to AIDS for 
initiating ART during incubation: 15–30 
years. Decreases in infectivity and 
increases in life expectancy for those 
initiating ART during primary infection 
were forced to be larger than for those 
initiating ART during incubation.
Investigates the role of primary infection in 
HIV transmission. Estimates that among all 
new infections only 11% occur during 
primary infection. The effect of ART during 
primary infection on transmission is 
therefore limited. However, in a 
community with higher risk behaviour 
among casual partnerships, the fraction of 
transmission attributed to primary 
infection increases to 25%.
Table 1: Summary of existing ART models, by date of publication. (Continued)
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(Wood et al [16], for example), as well as to predict the
likely impact of scaling up ART use.
To date, policies designed to ameliorate the HIV/AIDS
epidemic in Africa have been heavily based on policies
from industrialised countries [27]. However, the epidemi-
ological and economic contexts are so different that there
is an urgent requirement to assess whether existing policy
options and targets are optimal for resource-poor settings.
Clements et al 2004 [38] Dynamic, deterministic 
(based on previous models 
[4, 78])
MSM, Australia 1995–2006 Assumed a 10% annual increase in 
population-level risk behaviour from 1996. 
A stable proportion receive ART from 
1998, which then declines from 70% in 
2001 to a median of 50% of diagnosed on 
ART by 2006.
HIV incidence was predicted to have 
declined during 1996–1998 due to ART, 
with a slow increase 1998–2001 due to 
increased risk behaviour while ART usage 
remained fairly stable. From 2001, a 
continued increase in risk behaviour 
coupled with a moderate decline in ART 
use would lead to a 50% increase in 
incidence by 2006.
Auvert et al 2004 [26] Linear Township near 
Johannesburg South Africa, 
2002
Used results from cross-sectional study. 
Under WHO guidelines, all with CD4 
counts <200 initiated treatment. Under 
USDHHS guidelines, all with CD4 counts 
<350 or viral load >55,000 copies/mL 
initiated treatment. Reduction in infectivity 
due to ART calculated using infectivity 
estimates by viral load category used by 
Gray et al [2] and comparing change in 
distribution of viral load in the community 
with and without ART.
Investigated short term impact of ART on 
incidence. The proportion of infected 
subjects eligible for ART was 9.5% (95% CI 
6.1–14.9%) under WHO guidelines and 
56.3% (95% CI 49.1–63.2%) under 
USDHHS guidelines. The population 
impact of ART on HIV transmission is small 
(reduction in annual risk of transmission 
11.9% (95% CI 7.1–17.0%)) under WHO 
guidelines, but higher under USDHHS 
guidelines (71.8% (95% CI 64.5–77.5%))
Boily et al 2004 [30] Dynamic, deterministic MSM population STI (gonorrhoea) increasing HIV 
infectiousness is modelled dynamically. 
Stratified into 6 sexual activity groups with 
proportionate mixing. Two stages of HIV 
infection: incubation and AIDS. AIDS 
patients treated with ART resume the 
sexual activity of asymptomatic individuals 
within their activity class. ART reduces 
infectivity by 25% (pessimistic), 50–90% 
(moderate), 99% (optimistic). Treatment 
uptake rates: 10–90% per year, for AIDS 
patients only, or for all infected subjects 
Withdrawal rate (due to treatment failure, 
resistance and toxicity): 0–50% per year.
Zero to 55% new bacterial STI could be 
attributed to widescale ART use, due to 
more modest increases in risky behaviour 
(0–25%) at the population level. These 
increases have a negative impact on HIV if 
coverage is too low. Increasing ART 
coverage helps to prevent more HIV 
infections despite larger increases in risk 
behaviour and STI that is predicted to 
ensue. No individual-level increase in risk 
behaviour; population-level increases in 
risk behaviour over time are due to ART 
slowing the depletion of high-risk infected 
individuals, so these populations are 
replenished.
Salomon et al 2005 [22] The Goals model (linear 
spreadsheet model) (based 
on previous models [20, 
21])
Sub-Saharan Africa, 
calibrated to 3 regions: 
East, West/Central and 
Southern, up to 2020.
Goals model adjusts UNAIDS/WHO EPP 
(epidemic projection package) and 
Spectrum model incidence and prevalence 
estimates. 5 different risk groups (single 
and married men and women, and CSWs). 
Median increase in life expectancy due to 
ART: 3 years. No drug resistance. Includes 
STI transmission. 3 stages of infection: 
primary, incubation and symptomatic. ART 
reduces infectivity by 99% (optimistic) or 
66% (pessimistic). Number of partners 
reduced by 50% plus 2 times higher 
condom use (optimistic) or no change 
(pessimistic) for those treated. Risk 
behaviour of the general population does 
not change (optimistic), or condom use 
declines by 10% (pessimistic). Treatment 
uptake: 50% ART coverage (of those in 
need) by 2005, increasing to and remaining 
at 80% from 2010–2020. This "treatment-
centred" response, where little prevention 
activity occurs, was compared to a 
"prevention-centred" response where no 
ART scale-up occurred, and a "combined 
response", with optimistic and pessimistic 
assumptions of the effect of ART on 
prevention efforts being investigated.
Explored the potential impact of ART in 
the context of a broader strategy for HIV/
AIDS control, comparing deaths and new 
infections averted to baseline projections 
without interventions. A prevention-
centred strategy provides greater 
reductions in incidence and mortality 
reductions similar to those of treatment-
centred strategies by 2020, but more 
modest mortality benefits over the next 5–
10 years. If treatment scale-up leads to 
reduced effectiveness of prevention 
efforts, benefits (in terms of infections and 
HIV/AIDS deaths averted) are considerably 
smaller than for initiatives which 
complement each other. The number 
receiving ART in 2020 ranges from 9.2 
million in a pessimistic treatment-only 
scenario, to 4.2 million in a combined 
response scenario with positive treatment-
prevention synergies.
Wilson & Blower 2005 [19] Spatial model KwaZulu-Natal, South 
Africa
Incorporates heterogeneity in treatment 
accessibility with distance to health care 
facilities, and heterogeneous distribution of 
people infected with HIV.
Determining the optimal ART allocation 
strategy among health care facilities, aiming 
to maximise equity. Authors' strategy gave 
more equal access to ART than allocating 
therapy to the state capital only, or equal 
allocation to all health care facilities.
Table 1: Summary of existing ART models, by date of publication. (Continued)
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Dynamic model structures
Most dynamic models of HIV transmission investigating
the impact of ART are deterministic, with a frequency-
dependent (density-independent) transmission term.
This means that the rate of (sexual) contact between one
individual and others within a population does not
depend on the density of the population, as it would, for
example, in the case of contacts for air-borne infection
transmission. HIV transmission models often incorporate
relatively complex patterns of sexual behaviour, with
model populations stratified into sexual activity groups by
rate of partner change, and assuming different degrees of
mixing between groups. However, to date most models
specifically designed to examine ART impact have
assumed homogeneous risk behaviour (although some of
these models have investigated changes in risk behaviour
of the general population as a result of ART introduction
and/or a change upon diagnosis of HIV [4,5]). More real-
istic incorporation of sexual behaviour is likely to
improve the ability of models to capture the observed
timescale of African HIV epidemics, namely steady state
being reached over decades rather than centuries. Figure 1
shows projections from a homogeneous sexual activity
model, illustrating how, with a homogeneous popula-
tion, realistic prevalence levels (representing epidemics in
sub-Saharan Africa) can only be reached over unrealistic
timescales (a full description of the model is provided in
the Endnote). However, such homogeneous models can
simulate HIV epidemics over realistic timescales if they are
assumed to represent the 'at-risk proportion' of the total
population only. This means that the population is
crudely divided into two groups; one group practices no
risky behaviour at all, whereas the other has a relatively
high rate of (unprotected) sexual partner change. This
structure produces an epidemic curve over a realistic time-
frame (decades rather than centuries), without producing
unreasonably high prevalence levels for the entire popula-
tion (at-risk and not at-risk).
More sophisticated models incorporating sexual behav-
iour include partner models [28,29] and network models
[30,31]. Gray et al [2] use a stochastic simulation incorpo-
rating individuals and their contacts, although some
assumptions are not clear in the available publication.
The need for complexity will depend on the nature of the
research question [32]. For example, where changes in
sexual behaviour as a result of ART are to be investigated,
a more sophisticated description of sexual behaviour is
required [30]. Where the effect of ART on transmission is
to be investigated, a more realistic pattern of infectivity is
required [2,4]. However, while increased complexity can
make models more realistic, it also makes them more dif-
ficult to parameterise and it more difficult to analyse and
interpret model output.
Behaviour change
The possibility of widescale use of ART leading to changes
in patterns of risk behaviour, particularly a disinhibition
effect, has been of considerable concern. There are com-
peting possible effects; at the individual level, treated
patients may increase the frequency of sexual activity due
to the severity of their symptoms decreasing, but may
receive effective prevention counselling upon treatment
initiation, which would decrease the frequency of risky
activities. At the population level, in areas with substantial
treatment coverage and successful treatment outcomes,
there may be an increase in complacency among the gen-
eral population regarding an HIV diagnosis, leading to
increases in risk behaviour. Despite considerable debate
[11-15], this relationship has not been convincingly dem-
onstrated in industrialised countries where ART is readily
Model predictions of the effect of ART on a mature epi-demic, under various assumptionsFigure 1
Model predictions of the effect of ART on a mature 
epidemic, under various assumptions. Model simula-
tions of the potential impact of ART on a mature epidemic, 
varied by treatment uptake rate, reduction in infectivity due 
to treatment and impact on risk behaviour at the population 
level (see Endnote for model description). The model used 
only incorporates one stage of HIV infection and so individu-
als initiate treatment at an earlier stage of infection than is 
realistic, and there is homogeneous sexual mixing. Scenario 
A – ART uptake = 50% per year, sexual activity post ART = 
unchanged (2.5 partners per year), reduction in infectivity 
due to ART = 50-fold. Scenario B – ART uptake = 50% per 
year, sexual activity post ART halves (1.25 partners per 
year), reduction in infectivity due to ART = 50-fold. Scenario 
C – ART uptake = 50% per year, sexual activity post ART = 
unchanged (2.5 partners per year), reduction in infectivity 
due to ART = 1000-fold. Scenario D – ART uptake = 90% 
per year, sexual activity post ART = unchanged (2.5 partners 
per year), reduction in infectivity due to ART = 1000-fold. 
Scenario E – ART uptake = 90% per year, sexual activity post 
ART = reduced by 20% (2 partners per year), reduction in 
infectivity due to ART = 1000-fold.
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available. A recent paper suggests that recent increases in
risk-taking behaviour among MSM may be the result of
non-volitional changes at the individual level over time
[33]. The depletion of the pool of high-risk individuals in
the pre-ART era made it more difficult for the remaining
high risk-taking individuals to find partners to engage in
risky sex with, but ART has facilitated the differential
replenishment of this group. Therefore individuals who
previously had to reduce their levels of risky sex could
resume their initial high-risk behaviours.
The threat of behavioural disinhibition it is unlikely to be
an immediate concern as ART is rolled out in high preva-
lence, resource-poor settings, where initial coverage is
likely to be low and the effectiveness of ART programmes
remains to be seen. Furthermore, the behavioural effects
resulting from ART use in resource-poor settings are
unlikely to follow patterns of industrialised countries. A
person's decision to have sex, protected or unprotected, is
influenced by a different set of considerations in resource-
poor settings than those common in industrialised coun-
tries. Key is an individual's ability to negotiate her or his
own sexual activity – as defined by fear of stigma, finan-
cial need, or the status of women within society. An indi-
vidual is also less likely to be aware of his or her
serostatus, due to lack of testing facilities and/or fears
regarding a positive result. The provision of treatment
may increase interest in voluntary counselling and testing
(VCT) services, which may in turn lead to a decrease in fre-
quency of risk behaviour by those infected. In Cote
d'Ivoire for example, individuals reported low sexual
activity following an HIV diagnosis, and this was not
increased by the offer of ART [34]. Despite the inaccura-
cies of sexual behaviour data, these results are
encouraging.
Given that it is difficult to predict how individuals might
change their sexual behaviour as a result of ART introduc-
tion in different regions, models are faced with either
estimating behavioural parameters from epidemiological
data, or exploring pessimistic and optimistic scenarios
using parameter values assumed to be at the ends of the
spectrum of possible outcomes. Law et al 2001 modelled
the effect of ART on the HIV epidemic in Australia in 1996
among the homosexual population [4] and predicted the
outcome of the competing effects of increased life expect-
ancy, decreased infectiousness and increases in unsafe sex
of uninfected MSM on HIV incidence. Their assumption
of a range of no change to a doubling of risky sex was
essentially arbitrary, but demonstrated that increases in
sexual behaviour (and life expectancy) could negate the
beneficial impact of decreased infectiousness on inci-
dence. Blower et al 2000 produced similar results for the
homosexual population in San Francisco [5], again using
the range of no change to a doubling in sexual risk-taking.
Velasco-Hernandez et al have investigated the conditions
under which ART in HIV infected individuals may drive an
epidemic to extinction [1]. As can be shown by the model
output in Figure 1, for ART to eliminate HIV, an extensive
reduction in risk activity at the population level, accompa-
nying ART use (such as a 50% reduction in the partner
acquisition rate) is required, together with high levels of
treatment uptake and large decreases in infectiousness
induced by ART. As behaviour change is notoriously diffi-
cult to generate and initial coverage rates for ART in
resource-poor settings are likely to be low, this optimistic
scenario is highly unlikely.
The early impact of widescale ART use in resource-poor
settings where HIV prevalence is currently high will prob-
ably not involve substantial population-level increases in
risky behaviour. The effectiveness of local ART pro-
grammes will likely have to be demonstrated across a
broad swath of the population before the perceived threat
of AIDS as a disease declines. In lower prevalence regions
where high coverage rates are feasible, such changes may
occur. Careful monitoring of potential changes in risk
behaviour would be very useful, if feasible. Any model
designed to explore the impact of sexual behaviour
change in resource-poor settings, be it an increase or a
decrease, should explicitly model HIV diagnosis sepa-
rately from treatment initiation, as shown by Law et al [4],
because 1) it is knowledge of HIV status and the associ-
ated counselling that may change behaviour, 2) the
advent of therapy in the sick may change their desire and/
or ability for sexual functioning and 3) the attitude of
those who know they are infected with HIV may change
between not being treated, where they perceive a risk of
transmitting to partners, to being treated, where the mag-
nitude of risk may be perceived as smaller. This is one area
where the introduction of ART could be used for preven-
tion as well as treatment, through facilitating VCT.
Stage of HIV infection
Some researchers believe that ART could be used as a
direct prevention tool due to its effect on viral load lead-
ing to a decrease in infectivity and therefore incidence
[26,35,36]. However, the competing effects of increasing
prevalence due to the effect of ART on life expectancy and
potential behavioural disinhibition would make this a
risky strategy. Furthermore, models that predict dramatic
reductions in incidence due to ART have used unrealistic
treatment uptake rates. As described, some have argued
that even high prevalence (30%) epidemics can be driven
to extinction by ART, when assuming a treatment coverage
rate of 50% to 90% [1,5]. The 50% level was estimated
from data collected in a telephone sample interview of
462 MSM from four US cities conducted between Novem-
ber 1996 and February 1998 [37]. This was when HAART
was in its infancy and treatment was initiated in a large
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proportion of HIV positive individuals, regardless of
infection stage or CD4 count, because a "hit hard, hit
early" consensus existed for patient management. Further-
more, the study only included self-identified, HIV-posi-
tive MSM, and so individuals unaware of or reluctant to
admit their serostatus would have been missed. It is now
more common to initiate treatment at a later stage of
infection, due to side-effects and the risk of evolution of
drug resistance. The proportion of HIV-infected people
currently being treated, even in industrialised countries, is
likely to be substantially below that required for any pros-
pect of disease elimination.
More realistic patterns of ART use are incorporated in the
models of Law et al [4,38] and Gray et al [2], where the
proportion of individuals treated increases with severity
of HIV disease as determined by CD4 count [4] or plasma
viral load [2]. By explicitly modelling changes in infec-
tiousness and sexual activity over time, it has been shown
that ART alone cannot be relied upon as a sole prevention
tool.
Gray et al [2] and Nagelkerke et al [39] explicitly modelled
the impact of ART in resource-poor settings (Uganda, and
Botswana and India, respectively). Nagelkerke et al 2002
assumed that those receiving ART and infected with drug-
sensitive virus had zero infectivity, which does not reflect
the true situation, despite viral load being substantially
reduced [39]. Assumed rates of resistance evolution seem
optimistically low for ART use in resource-poor settings,
only being varied between 5% and 25% of those on ART
failing treatment per year, whereas rates as high as 60%
have been predicted by others [40-42]. Despite this the
model predicted that after transient success, ART would be
rendered ineffective within 30 years due to wide-scale
emergence of drug resistance, based on resistant virus
being as transmissible as sensitive virus.
Gray et al's conclusions were relatively pessimistic [2],
contrasting with Blower et al [5]. Gray et al concluded that
ART alone cannot control mature HIV epidemics such as
that in Rakai, Uganda. This conclusion concurs with Gar-
nett et al 2002 [43], who believe that ART cannot make an
impact on a mature epidemic unless treatment is initiated
with high coverage and earlier in infection (i.e. with
higher CD4 cell counts) than is currently recommended
in treatment guidelines. Such early treatment is unfeasible
financially and unwarranted clinically, since it would lead
to earlier evolution of resistance and treatment failure,
leaving individuals running out of treatment options, per-
haps even before the onset of AIDS.
The dependence of the epidemiological impact of ART use
on the timing of treatment initiation is worth considering
in more detail. The progress of HIV infection to AIDS can
broadly be divided into four stages: primary infection,
incubation, the period preceding AIDS ("pre-AIDS") and
AIDS. While there is much between- and within-patient
variation, on average, infectiousness is highest during pri-
mary infection, pre-AIDS and AIDS. Some experts believe
that primary infection carries the highest risk of transmis-
sion, because it is associated with high plasma HIV RNA
levels and continued sexual activity [44]. However, while
some studies are aiming to evaluate the effect of treating
individuals in primary infection [3], the vast majority of
HIV infections are not diagnosed until well into the incu-
bation period. If primary infection is defined as the period
before detectable antibodies against the virus emerge,
then testing can only identify those who have completed
the primary stage. However, if primary infection is used to
describe the high initial viraemia then infection could be
diagnosed before this has ended. Treatment could not
start earlier than the incubation stage which follows pri-
mary infection except in rare circumstances where expo-
sure is known to have occurred. In resource-poor settings,
diagnosis is frequently at a very late stage of infection
[45,46], partly because of the non-specific nature of symp-
toms and the difficulty in accessing healthcare. Therefore,
initiating treatment at diagnosis or when CD4 counts
descend to a certain benchmark, such as 350 or 200 cells/
mm3 (as recommended by current guidelines [25,47]),
will mean that the highly infectious period of primary
infection and the long period of incubation escape the
controlling effects of treatment.
In models examining the impact of ART on HIV incidence,
inclusion of the variation in infectiousness as a function
of infection stage is crucial for producing realistic predic-
tions. As ART can only be initiated upon HIV diagnosis, it
will have no effect on transmission from most individuals
undergoing primary infection, when risk of transmission
is high. By the time an individual has developed AIDS,
their sexual activity will have decreased, and so this group
of infected individuals will not contribute as much to HIV
transmission as the duration of this phase would suggest.
Figure 2 shows runs from a four-stage HIV infection
model, with various treatment coverage scenarios, deter-
mined by stage of infection. Treatment is introduced into
a population with a mature HIV epidemic and a high
basic reproductive number for the at-risk fraction of the
population (R0~5), so it is not surprising that even aggres-
sive implementation of ART to individuals, regardless of
stage of infection, cannot lead to elimination. Figure 2
illustrates that ART under more realistic assumptions
regarding treatment delivery, in terms of treatment initia-
tion, will have far less impact on incidence. In this model,
there is a single treatment regimen and high, but plausi-
ble, rates of drug resistance evolution (30% per year),
meaning that the effects on transmission are short-lived,
coinciding with the effectiveness of the regimen. This
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illustrates the urgent need for cheap and reliable second-
line treatment options to be available for ART roll-out.
Despite our view that Blower et al are over-optimistic [5],
Gray et al's assumptions of the effects of ART may simi-
larly be over-pessimistic [2]. The authors assume that ART
leads to an average proportional reduction in HIV log viral
load of between 26.8% and 43.6%, based on data from
the Women's Interagency HIV Study (WIHS) [48] and the
John Hopkins Clinic [49] respectively. However, other
studies distinguish between patients who respond to a
regimen (who typically experience reduction in viral load
to undetectable levels (<50 copies/ml)), those who do not
respond and those who subsequently experience treat-
ment failure (viral rebound). With these distinctions, an
individual responding successfully to ART will have a far
greater reduction in viral load than Gray et al assume. Fur-
thermore, the proportion reduction was the value
recorded one month and three months after treatment ini-
tiation for the WIHS and John Hopkins Clinic patients,
respectively. It can take much longer than this for com-
plete reduction of viral load, often to undetectable limits
[50] (models generally do not explicitly account for a
delay between treatment initiation and effect, but it can be
assumed that this is implicitly accounted for in the treat-
ment uptake rate). Gray et al also included the possibility
of behavioural disinhibition; the average number of part-
ners for those on treatment was increased by 50% or
100%. Again, the values appear pessimistic and were
essentially chosen arbitrarily, probably in order to com-
plement other models [4,5].
Emergence of ART drug resistance
Many models of ART have concentrated on predicting the
emergence and spread of ART drug resistance, which has
been of concern [51-54]. Once again it is very difficult to
make such predictions, as the spread of drug-resistant
virus is highly dependent on the replicative fitness of the
resistant strains that evolve and their ability to superinfect
individuals infected with wild-type strains (i.e. to co-
infect someone already infected with wild-type virus, and
successfully replicate). Superinfection is perhaps only
likely in the successfully treated individual, where sup-
pression of viral load allows the target cell population to
recover, hence increasing the chance of successful replica-
tion and establishment of a new strain. In the untreated
individual, it is unlikely that low frequency resistant virus,
typically less fecund than wild type in this environment,
would be able to compete against the established viral
population sufficiently successfully to allow long-term
persistence of the invading strain.
In a context where ART use is common in core groups, the
possibility of superinfection of those on ART means that
the likely maximum rate of spread of resistance epidemics
may be similar to the speed of the initial HIV epidemic.
HIV co-infection with different wild-type viruses [55,56],
and by wild-type strains re-infecting patients harbouring
drug-resistant viruses after a short period of treatment
interruption [57,58], have both been documented.
Chakraborty et al postulate that it is possible for patients
infected with wild type HIV-1 isolates and under success-
ful ART to become exposed to drug-resistant strains that
would have significant selective advantage, leading them
to outcompete the original wild-type strain and instigate
treatment failure [59]. They concede that the probability
of an individual undergoing successful treatment of a
wild-type strain being exposed to a drug-resistant strain is
low, but the large-scale roll-out of ART in high prevalence,
resource-poor settings may increase this probability
substantially.
The rate at which drug resistance evolves within the indi-
vidual is likely to become higher in resource-poor settings
than industrialised countries; even though there are
reports of patient adherence being no lower than in the
West [60], potential interruptions in supply due to trans-
port problems and a lack of sophisticated laboratory
monitoring systems will limit the success of any ART
Predictions of the impact of ART by stage of infection at which reatment is initia edFigure 2
Predictions of the impact of ART by stage of infec-
tion at which treatment is initiated. Predictions of the 
impact of the introduction of ART in terms of HIV incidence, 
by stage of infection at which treatment is initiated (for a 
brief description of the four stage infection model used, see 
Endnote). Scenario A – No treatment. Scenario B – ART 
uptake: AIDS patients only (after a mean of 1 month). Sce-
nario C – ART uptake: AIDS patients (after mean 1 month) 
and pre-AIDS (after mean 6 months). Scenario D – ART 
uptake: AIDS patients (after mean 1 month) and pre-AIDS 
(after mean 6 months) and incubation stage (after mean 4 
years). Scenario E – ART uptake: all four stages, after mean 1 
month.
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regimen. However, even with high levels of drug resist-
ance evolving within the individual ("secondary resist-
ance"), transmission of such strains ("primary
resistance"), while increasing in many industrialised set-
tings [54,61], is reported to be substantially less frequent
than for wild-type HIV [61,62], because there is usually a
fitness cost for mutations. Mathematical models may have
the ability to predict best- and worst-case scenarios for
resistance spread [39,63], but it must be conceded that the
degree to which drug resistance and risky behaviour
increase as ART use rolls out in Africa and other resource-
poor areas cannot yet be quantified.
Blower et al 2001 predicted that acquired resistance will
continue to rise, but transmitted resistance is likely to
increase only gradually, with a doubling time of around
four years and a predicted median of 15.6% of new HIV
infections likely to be resistant to antiretroviral drugs by
2005 [63]. This conclusion was due to an assumption that
of all possible ART-resistant HIV strains that could
possibly evolve, none could be as transmissible as wild-
type. The study also assumed that individuals infected
with ART-sensitive virus undergoing treatment cannot be
co-infected or superinfected by an ART-resistant strain.
Despite the conclusion that transmitted ART resistance
will stabilise at low levels, the predicted range around the
15.6% value is very wide (0.05% to 73.21%) [63]. The
authors argue that the higher values in the range generated
from their sensitivity analysis have a very low probability.
However, the choice of parameter distributions in the
Monte Carlo sampling of parameter space undertaken in
their study was arbitrary (in the sense of not being moti-
vated by prior data) and entirely determines the probabil-
ity of pessimistic scenarios.
The authors themselves acknowledge that they are "pre-
dicting the unpredictable" [63], but argue that their theo-
retical predictions [5] are in close agreement with
empirical data [64]. Both display an increase in primary
resistance between 1997 and 2001, but this is a short time
period and the increase may reflect the expansion in use
of ART over this time. Furthermore, the uncertainty inter-
val around predictions made by the authors is large
enough for a wide range of empirical data to fit the model.
Blower et al acknowledge that transmission of ART resist-
ance may vary widely by location and that frequent com-
parison to empirical data is necessary. However, Blower et
al in 2005 recommend that large-scale surveillance for
detecting transmitted resistance in Africa will be unneces-
sary for the next decade because transmitted drug resist-
ance will not reach more than 5% during that time [65].
This is due to the assumption that ART use will remain at
low levels, although the authors suggest that in urban
locations rates of treatment may be higher. They recom-
mend close monitoring of treated patients, but in areas
where resources are constrained, this is unlikely to be
practicable (WHO guidelines do not consider resistance
testing, or even viral load testing, to be a priority in these
regions [25,66]). We would argue that surveillance of the
prevalence of drug resistance among patients is required
in all locations where ART is used, and that the predictive
utility of models with high degrees of uncertainty in their
input parameters, and hence also their results, is limited.
In this context, it should be noted that increases in levels
of acquired resistance are not inevitable – in Switzerland,
where more than 80% of prescribed ART is dispensed by
one of the highly experienced Swiss HIV Cohort centres,
prevalence of drug-resistant HIV in newly infected indi-
viduals has been decreasing since 1996 [67]. However, we
would argue that such an effect is less likely in resource-
poor settings with restricted access to high-quality care
and laboratory facilities and potential problems of drug
sharing, black market resale of drugs and inappropriate
prescribing of mono and dual therapy outside of official
ART programmes [53]. The differences between ART pro-
grammes in industrialised and developing countries will
be so marked that predicting programme impact and pat-
terns of drug resistance from those in former setting is not
necessarily informative.
If one relaxes the assumption that no resistant strain can
exceed the transmission fitness of wild-type even in the
presence of ART use, even greater variation in predicted
levels of transmitted drug resistance after 10 years of ART
provision is possible (Figure 3). The scenarios illustrated
assume a conservative rate of 10% per year for the evolu-
tion of resistance in the treated patient and do not allow
for the possible enhancement of that rate in individuals
suffering viral rebound (an increase in viral load follow-
ing a previous decrease due to ART) without initial resist-
ance, but who are then maintained on the same regimen
(due to a lack of virological testing). Nevertheless, the
results show that if a relatively fit variant emerged, the
effectiveness of current ART regimens could be compro-
mised after a very short period. There appears to be little
change in model results when superinfection alone is
allowed to occur, but when heterogeneous sexual activity
is incorporated, resistance transmission is predicted to
emerge more rapidly. This is due to superinfection allow-
ing resistance to be transmitted through core groups
receiving ART.
These results do not suggest a likelihood of drug resistance
transmission but merely demonstrate the potential effects
of various scenarios. It is more for biological studies (in
particular resistance testing) and within-host models of
HIV infection to examine the possibility that such strains
could emerge [68-70]. Even in instances where laboratory
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tests reveal infections with virus deemed "resistant" to
more than one drug class (either phenotypically or
genotypically), these infections often still respond to
treatment. A multidrug-resistant HIV strain would require
a large number of compensatory mutations to be of a
comparable fitness to wild type strains. However, ongoing
treatment pressure in the presence of viral rebound could
lead to sequential mutations increasing the fitness of a
resistant strain; therefore, there is an argument for close
monitoring of patients and implementation of drug resist-
ance surveillance systems as ART is rolled out in resource-
poor settings.
Parameterisation
To aid the design of successful ART programmes in
resource-poor settings, more information on the impact
of ART provision is crucial – data on morbidity and mor-
tality, tolerability, treatment failure and the possible
emergence of drug resistant strains are very important.
This information also increases the reliability of model
Model predictions of transmission of ART drug resistance by relative fitness of strainsFigure 3
Model predictions of transmission of ART drug resistance by relative fitness of strains. Predictions of the spread of 
transmitted (primary) ART resistance under various scenarios, using a simplified ART model (see Endnote). Model output is 10 
years after ART introduction. ART is introduced once the epidemic has reached equilibrium. Superinfection refers to the infec-
tion with ART-resistant HIV of individuals previously infected with ART-sensitive HIV and successfully undergoing treatment. 
These are the only individuals without viral outgrowth, and thus will have a pool of target cells rendering them susceptible to 
infection. Evolution of drug resistance within an individual is at a rate of 10% per year.
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predictions by providing more accurate ranges of parame-
ter estimates. Population-level monitoring for changes in
risk behaviour and patterns of ARV drug resistance are also
required. Information on the performance of ART pro-
grammes in these settings is starting to be generated. Pilot
programmes such as the Médecins Sans Frontières (MSF)
initiatives (established in seven low- and middle-income
countries: Malawi, Kenya, South Africa, Cameroon, Cam-
bodia, Thailand and Guatemala) are starting to report
back preliminary findings. The six-month outcomes from
the MSF projects were positive [71]: the probability of sur-
vival at six months was estimated as 89.5% (95% CI 86.8–
92.1), with high patient attendance and adherence rates
comparable to those in industrialised countries. However,
pilot programmes may not be representative of future
large-scale ART roll-out, where health-care infrastructure
and expertise are likely to be poorer. Other programmes,
such as those of the Drug Access Initiative (DAI), formed
in 1998 by UNAIDS in collaboration with the Ministries
of Health of Chile, Côte d'Ivoire, Uganda and Vietnam,
have been running for longer. Reports from the first two
years of the initiatives in Côte d'Ivoire have been positive
[72], with immunologic and virologic outcomes similar
to those reported from industrialised countries. The only
resource-poor country to implement ART provision on a
large scale is Brazil, which has made ART available free of
charge to all eligible patients since 1996, and has pro-
duced positive outcomes [73]. The experience of Brazil
can give information on the impact of long-term, large-
scale ART provision, but is a very different setting to sub-
Saharan Africa. As with data from industrialised countries,
care must be taken in interpreting and assessing the appli-
cability of results. Modelling provides the tools to predict
the consequences of possible activity; by constraining our-
selves to examining only those scenarios that are sup-
ported by current, gathered data, we can be ignoring
other, distinct possibilities, such as the case in which an
ART-resistant strain as fit as wild-type could evolve.
Conclusion
We have argued that HIV transmission models predicting
the impact of ART use should incorporate a realistic pro-
gression through stages of HIV infection in order to realis-
tically capture the timing of treatment initiation. Further
elaboration of models is required (depending on the
research question being posed), in areas such as time of
diagnosis, sexual behaviour and assumptions regarding
drug resistance evolution and transmission. All modelling
studies are eventually dependent on the availability of set-
ting-specific surveillance and behavioural data, and col-
lection of such data is important for all regions where
large scale ART use is introduced.
More investigation is required in order to determine the
effect of introducing ART on a substantial scale in
resource-poor settings with different stages and magni-
tudes of HIV epidemic. Models addressing questions of
ART implementation in such settings, utilising data from
fledgling ART projects where possible, will be of great use
in designing cost effective programmes.
List of abbreviations
AIDS Acquired Immunodeficiency Syndrome
ART Antiretroviral therapy
HAART Highly Active Antiretroviral Therapy
HIV Human Immunodeficiency Virus
MSM Men who have Sex with Men
PMTCT Prevention of Mother to Child Transmission
VCT Voluntary Counselling and Testing
Endnote
Model assuming one stage of HIV infection
The model assuming one-stage of HIV infection, used to
produce Figure 1, is illustrated in Figure 4, with state vari-
ables, parameter symbols and model equations given
below. Superinfection with an ART-resistant strain is pos-
sible for individuals undergoing successful treatment only
( , S = ART-sensitive, T = treated), as these are the only
individuals without viral outgrowth, and thus will have a
pool of target cells rendering them susceptible to infec-
tion. Treatment failure can occur with (κ) or without (f)
the evolution of drug resistance. Individuals who have
developed treatment failure not accompanied by
resistance ( , F = treatment failure) are at increased risk
of developing drug resistance (κF) because of viral replica-
tion in the presence of continued drug pressure. Figure 3
uses a version of this one-stage model, modified to incor-
porate heterogeneous sexual mixing, with four different
sexual activity groups.
The advantage of one-stage models of infection is that
they are relatively simple and analytically tractable; that is,
the relationship between each parameter and the outcome
of the models, for example in terms of R0[1], can be
exactly specified without recourse to simulation and sen-
sitivity analysis. However, while a model should not
incorporate complexity for its own sake, stages of HIV
infection play a crucial role in the impact of ART, because
treatment is only initiated at late stages of infection, and
infectivity and sexual activity vary with the course of infec-
tion. Similarly, incorporating heterogeneous sexual activ-
ity within a model is more important for some research
questions than for others. If we want to investigate the
potential impact of a transmissible ARV-resistant HIV
IS
T
IS
TF
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strain through a population, its spread would appear very
different in a model of homogeneous sexual activity, com-
pared to one with heterogeneity and various assumptions
regarding mixing between activity classes, where infection
would travel through core groups first before spreading
into the general population.
State Variables
S = susceptible individuals
 = ART-sensitive HIV infected individuals, untreated
 = ART-sensitive HIV infected individuals, treated
 = ART-sensitive HIV infected individuals, treated but
viral rebound
 = ART-sensitive HIV infected individuals, suffered
viral rebound, withdrawn from treatment
 = ART-resistant HIV infected individuals, treated
 = ART-resistant HIV infected individuals, untreated
 = ART-resistant HIV infected individuals (transmit-
ted resistance), untreated
 = ART-resistant HIV infected individuals (transmitted
resistance), treated
 = ART-resistant HIV infected individuals (transmit-
ted resistance), withdrawn from treatment
λS = force of infection for ART-sensitive virus phenotype
Model of HIV transmission and treatment, with one stage of infection onlyFigure 4
Model of HIV transmission and treatment, with one stage of infection only. Schematic illustration of the structure of 
the one stage HIV transmission model. 1° Res designates those with primary (transmitted) resistance, while 2° Res designates 
those with secondary (acquired) resistance. ART-Sens denotes people infected with ART-sensitive virus. For clarity, death 
rates are not shown.
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λR = force of infection for ART-resistant virus phenotype
(and force of (super)infection for ART-resistant virus phe-
notype, infecting an HIV wild type infected individual
under treatment pressure)
Parameters
For individuals of infection status :
i refers to viral phenotype (S (ART-sensitive) or R (ART-
resistant));
j refers to treatment status (U (untreated) or T (treated)).
σN0 entry into model population (rate of recruitment into
sexually active class). N0 is the size of the population at
time t = 0.
µ death rate due to causes other than HIV infection
 excess death rate due to HIV infection for an infected
individual in class 
γS treatment uptake rate for individuals infected with ART-
sensitive HIV
γR treatment uptake rate for individuals infected with ART-
resistant HIV
f rate of treatment failure (viral rebound) without ART
resistance evolution
κ rate of resistance evolution without previous viral
rebound
κF rate of resistance evolution with previous viral rebound
αS rate of treatment withdrawal for individuals initially
infected with ART-sensitive HIV
αR rate of treatment withdrawal for individuals initially
infected with ART-resistant HIV
 HIV transmission probability per partnership for an
infected individual in class 
c Number of sexual partnerships per year
 Probability of  transmitting ART-resistant HIV
 Probability of  transmitting ART-resistant HIV
 Probability of  transmitting ART-resistant HIV
 Probability of  transmitting ART-resistant HIV
ι Factor reduction in transmissibility for an infected indi-
vidual in class 
Transmission equations
The forces of infection for ART-sensitive (λS) and ART-
resistant (λR) HIV are given below. They are determined
by the infectiousness of individuals in each class (β) and
the probability that ART-resistant rather than ART-sensi-
tive virus is transmitted in the case of mixed infections
(ω).
Model assuming four stages of HIV infection
The model used to produce Figure 2 is essentially the same
as for the one stage infection model, but with infection
divided into four stages (primary infection, incubation,
pre-AIDS and AIDS) as shown in Figure 5. The forces of
infection are determined by the infectiousness of
individuals in each class, the probability that ART-resist-
ant rather than ART-sensitive virus is transmitted in the
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case of mixed infections and the rates of sexual partner
change, which decrease as individuals reach the final stage
(AIDS). The rest of the model structure is as for the one-
stage model. Full details of this model, equations and
parameter estimates are not shown here but are available
on request.
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